CMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2015 Mar 28

PMID 25815459

Citations 18

Authors

Nele Van Der Steen

Patrick Pauwels

Ignacio Gil-Bazo

Eduardo Castanon

Luis Raez

Federico Cappuzzo

Christian Rolfo

Affiliations

Soon will be listed here.

Abstract

In the last decade, the tyrosine kinase receptor cMET, together with its ligand hepatocyte growth factor (HGF), has become a target in non-small cell lung cancer (NSCLC). Signalization via cMET stimulates several oncological processes amongst which are cell motility, invasion and metastasis. It also confers resistance against several currently used targeted therapies, e.g., epidermal growth factor receptor (EGFR) inhibitors. In this review, we will discuss the basic structure of cMET and the most important signaling pathways. We will also look into aberrations in the signaling and the effects thereof in cancer growth, with the focus on NSCLC. Finally, we will discuss the role of cMET as resistance mechanism.

Citing Articles

Design, synthesis and biological evaluation of thienopyridine derivatives as c-Met kinase inhibitors.

Xie T, Hu W, You L, Wang X Mol Divers. 2024; .

PMID: 39356364 DOI: 10.1007/s11030-024-10998-3.

Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation.

Huang S, Long Y, Gao Y, Lin W, Wang L, Jiang J Exp Hematol Oncol. 2024; 13(1):97.

PMID: 39354638 PMC: 11443824. DOI: 10.1186/s40164-024-00565-9.

Genomic instability in congenital lung malformations in children.

Rodrigues de Moura R, Patrizi S, Athanasakis E, Schleef J, Pederiva F, dAdamo A Pediatr Surg Int. 2024; 40(1):248.

PMID: 39237666 DOI: 10.1007/s00383-024-05835-5.

Savolitinib: A Promising Targeting Agent for Cancer.

Lee T, Kim J, Lee M, Cho I, Paik W, Ryu J Cancers (Basel). 2023; 15(19).

PMID: 37835402 PMC: 10571651. DOI: 10.3390/cancers15194708.

Targeting Amplification: Opportunities and Obstacles in Therapeutic Approaches.

Kumaki Y, Oda G, Ikeda S Cancers (Basel). 2023; 15(18).

PMID: 37760522 PMC: 10526812. DOI: 10.3390/cancers15184552.

References

Kopitz C, Gerg M, Bandapalli O, Ister D, Pennington C, Hauser S . Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res. 2007; 67(18):8615-23. DOI: 10.1158/0008-5472.CAN-07-0232. View

Elia G, Ren Y, Lorenzoni P, Zarnegar R, Burger M, Rusciano D . Mechanisms regulating c-met overexpression in liver-metastatic B16-LS9 melanoma cells. J Cell Biochem. 2001; 81(3):477-87. DOI: 10.1002/1097-4644(20010601)81:3<477::aid-jcb1061>3.0.co;2-b. View

Tyner J, Fletcher L, Wang E, Yang W, Rutenberg-Schoenberg M, Beadling C . MET receptor sequence variants R970C and T992I lack transforming capacity. Cancer Res. 2010; 70(15):6233-7. PMC: 2913476. DOI: 10.1158/0008-5472.CAN-10-0429. View

Wang R, Kobayashi R, Bishop J . Cellular adherence elicits ligand-independent activation of the Met cell-surface receptor. Proc Natl Acad Sci U S A. 1996; 93(16):8425-30. PMC: 38687. DOI: 10.1073/pnas.93.16.8425. View

Parachoniak C, Luo Y, Abella J, Keen J, Park M . GGA3 functions as a switch to promote Met receptor recycling, essential for sustained ERK and cell migration. Dev Cell. 2011; 20(6):751-63. PMC: 3115551. DOI: 10.1016/j.devcel.2011.05.007. View

Gherardi E, Youles M, Miguel R, Blundell T, Iamele L, Gough J . Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A. 2003; 100(21):12039-44. PMC: 218709. DOI: 10.1073/pnas.2034936100. View

Mars W, Zarnegar R, Michalopoulos G . Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am J Pathol. 1993; 143(3):949-58. PMC: 1887222. View

Preusser M, Streubel B, Berghoff A, Hainfellner J, von Deimling A, Widhalm G . Amplification and overexpression of CMET is a common event in brain metastases of non-small cell lung cancer. Histopathology. 2014; 65(5):684-92. DOI: 10.1111/his.12475. View

Basile J, Afkhami T, Gutkind J . Semaphorin 4D/plexin-B1 induces endothelial cell migration through the activation of PYK2, Src, and the phosphatidylinositol 3-kinase-Akt pathway. Mol Cell Biol. 2005; 25(16):6889-98. PMC: 1190270. DOI: 10.1128/MCB.25.16.6889-6898.2005. View

10.

Kajiya K, Hirakawa S, Ma B, Drinnenberg I, Detmar M . Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J. 2005; 24(16):2885-95. PMC: 1187946. DOI: 10.1038/sj.emboj.7600763. View

11.

Ogunwobi O, Puszyk W, Dong H, Liu C . Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma. PLoS One. 2013; 8(5):e63765. PMC: 3665785. DOI: 10.1371/journal.pone.0063765. View

12.

Hoeflich K, Luo J, Rubie E, Tsao M, Jin O, Woodgett J . Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature. 2000; 406(6791):86-90. DOI: 10.1038/35017574. View

13.

Fixman E, Fournier T, Kamikura D, Naujokas M, Park M . Pathways downstream of Shc and Grb2 are required for cell transformation by the tpr-Met oncoprotein. J Biol Chem. 1996; 271(22):13116-22. DOI: 10.1074/jbc.271.22.13116. View

14.

Orian-Rousseau V, Chen L, Sleeman J, Herrlich P, Ponta H . CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 2002; 16(23):3074-86. PMC: 187488. DOI: 10.1101/gad.242602. View

15.

Ide T, Kitajima Y, Miyoshi A, Ohtsuka T, Mitsuno M, Ohtaka K . Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway. Int J Cancer. 2006; 119(12):2750-9. DOI: 10.1002/ijc.22178. View

16.

Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L . Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res. 2005; 11(16):5878-85. DOI: 10.1158/1078-0432.CCR-04-2618. View

17.

Montesano R, Soriano J, Malinda K, Ponce M, Bafico A, Kleinman H . Differential effects of hepatocyte growth factor isoforms on epithelial and endothelial tubulogenesis. Cell Growth Differ. 1998; 9(5):355-65. View

18.

Yu H, Pardoll D, Jove R . STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009; 9(11):798-809. PMC: 4856025. DOI: 10.1038/nrc2734. View

19.

Fan S, Gao M, Meng Q, Laterra J, Symons M, Coniglio S . Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene. 2005; 24(10):1749-66. DOI: 10.1038/sj.onc.1208327. View

20.

Graziani A, Gramaglia D, dalla Zonca P, Comoglio P . Hepatocyte growth factor/scatter factor stimulates the Ras-guanine nucleotide exchanger. J Biol Chem. 1993; 268(13):9165-8. View